publication venue for
- Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. 2022
- Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. 2022
- Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer. 2025
- Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis. 2025
- Ultrasound echogenicity is complementary to PI-RADS for risk stratification of clinically significant prostate cancer. 2025
- Racial variation in the advanced prostate cancer genome. 2025
- Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.. 28. 2024
- Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.. 28. 2024
- Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. 2024
- Price transparency of prostate cancer care in the United States: An analysis of pricing and disclosure following the centers for medicare and medicaid mandate.. 27. 2023
- Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.. 26. 2022
- Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes.. 25. 2022
- Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).. 25. 2022
- Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.. 25. 2022
- Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.. 25. 2021
- Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.. 24. 2021
- Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.. 24. 2021
- Temporal trends in the number of men electing for conservative management for low-risk prostate cancer in the United States.. 23. 2020
- Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis.. 24. 2020
- Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.. 23. 2020
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.. 22. 2018
- Molecular alterations in prostate cancer and association with MRI features.. 20. 2017
- Periprostatic adipose inflammation is associated with high-grade prostate cancer.. 20. 2017
- Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.. 20. 2017
- Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.. 20. 2017
- Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy.. 20. 2016
- Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.. 19. 2016
- The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy.. 19. 2016
- In vivo prostate cancer detection and grading using restriction spectrum imaging-MRI.. 19. 2016
- Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.. 18. 2015
- The diffusion of minimally invasive radical prostatectomy in the United States: a case study of the introduction of new surgical devices.. 18. 2014
- The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.. 17. 2014
- Androgen dynamics and serum PSA in patients treated with abiraterone acetate.. 17. 2014
- Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.. 17. 2013
- Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy.. 16. 2013
- Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.. 16. 2013
- The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.. 13. 2010
- Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.. 11. 2007
- Effective antigen cross-presentation by prostate cancer patients' dendritic cells: implications for prostate cancer immunotherapy.. 7. 2004
- Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible.. 6. 2003
- In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.. 5. 2002
- The comparative values of bone marrow aspirate and trephine for obtaining bone scan-targeted metastases from hormone-refractory prostate cancer.. 5. 2002
- Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.. 4. 2001
- The impact of sexual and urinary dysfunction on health-related quality-of-life (HRQOL) following radical prostatectomy (RP).. 3. 2000
- Clinical and pathologic significance of T1c adenocarcinoma of the prostate cancer.. 2. 1999
- Editorial.. 2. 1999
- Editorial.. 2. 1999
- Editorial.. 2. 1999
- Pathologic progression of autochthonous prostate cancer in the TRAMP model.. 2. 1999
- The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.. 2. 1999
- Editorial.. 1. 1998
- Unravelling the confusions in prostatic disease.. 1. 1998
- Editorial.. 1. 1997
- Editorial.. 1. 1997
- Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen.. 1. 1997
- Photoselective vaporization of the prostate (GreenLight PV): lessons learnt after 3500 procedures. 2007
- Identifying the best candidate for focal therapy: a comprehensive review. 2024
- Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2). 2024
- Ejaculatory function after radiotherapy for prostate cancer: a systematic review and meta-analysis. 2024
- Artificial intelligence applications in prostate cancer. 2023
- PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. 2021
- Clinical considerations for the management of androgen indifferent prostate cancer. 2021
- The very-high-risk prostate cancer: a contemporary update. 2016
- Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. 2009
- The emerging role of the PI3-K-Akt pathway in prostate cancer progression. 2005
- Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). 2024